The ultra high risk approach to define psychosis risk

Current Pharmaceutical Design

Volumn 18, Issue 4, 2012, Pages 346-350

  Yung, Alison R ^a   Fusar Poli, Paolo ^b   Nelson, Barnaby ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Prodrome; Psychosis; Schizophrenia

Indexed keywords

FISH OIL; OLANZAPINE; PLACEBO; RISPERIDONE;

ARTICLE; AT RISK MENTAL STATE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FALSE POSITIVE RESULT; HUMAN; MENTAL HEALTH; MENTAL HEALTH SERVICE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; RISK FACTOR; SYMPTOMATOLOGY; TREATMENT RESPONSE;

ANXIETY; EARLY DIAGNOSIS; HUMANS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISK FACTORS; SLEEP DISORDERS;

EID: 84856527977     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799316299     Document Type: Article

References (58)

1. Insel TR. Rethinking schizophrenia. Nature 2010; 468: 187-193.
2. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: Past and current conceptualizations. Schizophrenia Bulletin 1996; 22: 353-370.
3. Hafner H, Maurer K, Trendler G, Heiden Wad, Schmidt M, Konnecke R. Schizophrenia and depression: Challenging the paradigm of two separate diseases--A controlled study of schizophrenia, depression and healthy controls. Schizophrenia Research 2005; 77: 11-24.
4. Moller P, Husby R. The initial prodrome in schizophrenia: searching for naturalistic core dimensions of experience and behavior. Schizophrenia Bulletin 2000; 26: 217-232.
5. Varsamis J, Adamson JD. Early schizophrenia. Canadian Psychiatric Association Journal 1971; 16: 487-497.
6. Scott J, Chant D, Andrews G, McGrath J. Psychotic-like experiences in the general community: The correlates of CIDI psychosis screen items in an Australian sample. Psychological Medicine 2006; 36: 231-238.
7. Tien AY. Distributions of hallucinations in the population. Social Psychiatry & Psychiatric Epidemiology 1991; 26: 287-292.
8. van Os J, Hanssen M, Bijl RV, Vollebergh W. Prevalence of psychotic disorder and community level of psychotic symptoms: An urban-rural comparison. Archives of General Psychiatry 2001; 58: 663-668.
9. Van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L. A sytematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistenceimpairment model of psychotic disorder. Psychological Medicine 2009; 39: 179-195.
10. Yung AR, Nelson B, Baker K, Buckby J, Baksheev G, Cosgrave E. Psychotic-like experiences in a community sample of adolescents: implications for the continuum model of psychosis and prediction of schizophrenia. Aust N Z J Psychiatry 2009; 43: 118-128.
11. Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12- month follow up of a high-risk (prodromal) group. Schizophrenia Research 2003; 60: 21-32.
12. Yung AR, Nelson B. Young people at ultra high risk for psychosis: a research update. Early Intervention in Psychiatry 2011; 5 Suppl 1 52-57
13. Schultze-Lutter F. Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr Bull 2009; 35: 5-8.
14. Klosterkotter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001; 58: 158-164.
15. Bell RQ. Multiple-risk cohorts and segmenting risk as solutions to the problem of false positives in risk for the major psychoses. Psychiatry 1992; 55: 370-381.
16. Hafner H, Maurer K, Loffler W, A. R-R. The influence of age and sex on the onset and early course of schizophrenia. British Journal of Psychiatry 1993; 162: 80-86.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association: Washington DC 1994.
18. Yung A, Yuen H, McGorry P, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Australian and New Zealand Journal of Psychiatry 2005; 39: 964-971.
19. Cornblatt B, Lencz T, Obuchowski M. The schizophrenia prodrome: Treatment and high-risk perspectives. Schizophrenia Research 2002; 54: 177-86.
20. Broome MR, Woolley JB, Johns LC, et al. Outreach and support in south London (OASIS): Implementation of a clinical service for prodromal psychosis and the at risk mental state. European Psychiatry 2005; 20: 372-378.
21. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull 1996; 22: 283-303.
22. Miller TJ, McGlashan TH, Rosen JL, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: Preliminary evidence of interrater reliability and predictive validity. American Journal of Psychiatry 2002; 159: 863-865.
23. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Archives of General Psychiatry 2008; 65: 28-37.
24. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull 2003; 29: 703-715.
25. Fusar-Poli P, Borgwardt S, Valmaggia L. Heterogeneity in the assessment of the at-risk mental state for psychosis. Psychiatr Serv 2008; 59: 813.
26. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophrenia Bulletin 2003; 29: 703-715.
27. Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry 2005; 39: 964-971.
28. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008; 65: 28-37.
29. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: Psychopathology and clinical features. Schizophrenia Research 2004; 67: 131-142.
30. Riecher-Rössler A, Gschwandtner U, Aston J, et al. The Basel early-detection-of-psychosis (FEPSY)-study design and preliminary results. Acta Psychiatrica Scandinavica 2007; 115: 114-125.
31. Ruhrmann S, Salokangas RK, Linszen D, et al. EPOS - sample characteristics, transition rates and psychopathological predictors. European Psychiatry 2007; 22: s64.
32. Lam M, Hung S, Chen E. Transition to psychosis: 6-month followup of a Chinese high-risk group in Hong Kong. Australian and New Zealand Journal of Psychiatry 2006; 40: 414-420.
33. Kwon JS, Shim GS, Park HY, Jang JH. Current concept of prodrome from the experience of the Seoul Youth Clinic high risk cohort in Korea. Clinical Neuropsychiatry: Journal of Treatment Evaluation 2010; 7: 56-62.
34. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry 2002; 59: 921-928.
35. Phillips LJ, McGorry PD, Yuen HP, et al. Medium term follow-up of a randomized controlled trial of interventions for young people at Ultra High Risk of psychosis. Schizophrenia Research 2007; 96: 25-33.
36. McGlashan TH, Zipursky RB, Perkins D, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry 2006; 163: 790-799.
37. Morrison AP, French P, Walford L, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: Randomised controlled trial. British Journal of Psychiatry 2004; 185: 291-297.
38. Morrison AP, French P, Parker S, et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultra high risk. Schizophrenia Bulletin 2007; 33: 682-687.
39. Amminger GP, Schäfer M, Papageorgiou K, et al. Long-Chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Archives of General Psychiatry 2010; 67: 146-154.
40. Phillips LJ, Nelson B, Yuen HP, et al. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics. Australian and New Zealand Journal of Psychiatry 2009; 43: 818-829.
41. Yung AR, Phillips LJ, Nelson B, et al. Randomized controlled trial of interventions for young people at Ultra High Risk of psychosis: 6 month analysis J Clin Psychiatry 2011; 72: 430-440.
42. Yung AR, Yuen HP, Berger G, et al. Declining transition rate in Ultra High Risk (prodromal) services: dilution or reduction of risk? Schizophr Bull 2007; 33: 673-681.
43. Yung A, Stanford C, Cosgrave E, et al. Testing the Ultra High Risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophrenia Research 2006; 84: 57-66.
44. Eaton WW, Romanoski A, Anthony JC, Nestadt G. Screening for psychosis in the general population with a self-report interview. J Nervous Mental Disease 1991; 179: 689-693.
45. Poulton R, Caspi A, Moffitt TE, Cannon M, Murray R, Harrington H. Children's self-reported psychotic symptoms and adult schizophreniform disorder: A 15-year longitudinal study. Archives of General Psychiatry 2000; 57: 1053-1058.
46. Yung AR, Nelson B, Stanford C, et al. Validation of "prodromal" criteria to detect individuals at Ultra High Risk of psychosis: 2 year follow up. Schizophr Res 2008; 105: 10-17.
47. Carpenter WT. Anticipating DSM-V: Should Psychosis Risk Become a Diagnostic Class? Schizophr Bull 2009; 35: 841-843.
48. Carpenter WT. Should Attenuated Psychosis Syndrome be a DSM- 5 diagnosis? American Journal of Psychiatry 2011; 168: 460-463.
49. Woods SW, Addington J, Cadenhead KS, et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophrenia Bulletin 2009; 35: 894-908.
50. Woods SW, Walsh BC, Saksa JR, McGlashan TH. The case for including attenuated Psychotic Symptoms Syndrome in DSM-5as a psychosis risk syndrome. Schizophrenia Research 2010; 123: 199-207.
51. Corcoran C, First MB, Cornblatt B. The psychosis risk syndrome and its proposed inclusion in the DSM-V: A risk-benefit analysis. Schizophrenia Research 2010; 120: 16-22.
52. Yung AR, Nelson B, Thompson A, Wood SJ. Should a "Risk Syndrome for Psychosis" be included in the DSMV? Schizophr Res 2010; 120: 7-15.
53. Corcoran C, Malaspina D, Hercher L. Prodromal interventions for schizophrenia vulnerability: The risks of being at risk. Schizophrenia Research 2005; 73: 173-84.
54. Drake R, Lewis S. Valuing prodromal psychosis: What do we get and what is the price? Schizophrenia Research 2010; 120: 38-41
55. Kaymaz N, van Os J. DSM-5 and the 'Psychosis Risk Syndrome': Babylonic confusion. Psychosis: Psychological, Social and Integrative Approaches 2010; 2: 100-103.
56. Yang LH, Wonpat-Borja AJ, Opler MG, Corcoran CM. Potential stigma associated with inclusion of the psychosis risk syndrome in the DSMV: An empirical question. Schizophr Res 2010; 120: 42-48.
57. Ross CA. DSM-5 and the 'Psychosis Risk Syndrome': Eight reasons to reject it. Psychosis: Psychological, Social and Integrative Approaches 2010; 2: 107-110.
58. Cooper R. What is wrong with the DSM? History of Psychiatry 2004; 15: 5-25.